Overview

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Status:
Completed
Trial end date:
2018-01-29
Target enrollment:
Participant gender:
Summary
The purpose of the study is to establish the pharmacokinetic profile of omigapil in paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of omigapil. Funding source - FDA OOPD
Phase:
Phase 1
Details
Lead Sponsor:
Santhera Pharmaceuticals